Embecta have received clearance from the FDA in the US for a fully disposable patch pump with a 300-unit insulin reservoir. The new system is specifically designed for adults with type 1 and type 2 diabetes, addressing a crucial gap in diabetes medtech.
A tubeless patch pump with greater insulin capacity
The new patch pump stands out with its 300-unit insulin reservoir, making it an ideal solution for individuals with type 2 diabetes who often need larger doses - most insulin delivery systems are tailored to the needs of those with type 1 diabetes. Embecta’s patch pump recognizes the unique challenges faced by people with type 2 diabetes. The larger insulin reservoir means fewer refills and less frequent management, providing a more convenient option for users transitioning from multiple daily injections to pump therapy.
A recent study demonstrated that the 300-unit reservoir could meet the insulin needs of 64% of adults with type 2 diabetes for a three-day wear period, significantly higher than the 38% achievable with a 200-unit reservoir.
Convenience
Embecta’s patch pump is fully disposable and tubeless, designed for up to three days of use. It offers both basal and bolus insulin delivery, providing flexibility in managing daily insulin needs. The system includes a controller with Bluetooth® wireless technology and a color touchscreen, which simplifies insulin delivery adjustments and enhances the overall user experience.
Future Plans
Looking ahead, Embecta is working on developing a closed-loop system that incorporates an insulin-dosing algorithm, aiming for future FDA submissions to broaden their product range. This development will further streamline diabetes management, reducing the manual inputs required by users and enhancing overall efficiency.
Conclusion
Embecta’s new insulin patch pump is a notable advancement in diabetes technology, particularly for individuals with type 2 diabetes who need higher insulin doses. Its larger insulin reservoir, combined with its tubeless, disposable design, offers a more convenient and user-friendly option for managing diabetes. With plans for further innovation, Embecta continues to push boundaries in insulin delivery, offering promising solutions for the future of diabetes care.
Reference
Disclaimer
Blogs and publications on this website are independent of any involvement by medtech companies or diabetes related charities. To ensure there is no bias, we do not accept any products, freebies or other material from any medtech provider. Except where credited otherwise, all materials are copyright ©️Love My Libre Ltd.
Love My Libre is not associated or affiliated with Abbott or FreeStyle Libre. Content here and on our website www.lovemylibre.com does not constitute medical advice or replace the relationship between you and healthcare professionals nor the advice you receive from them.
The author of this blog has type 1 diabetes and uses the FreeStyle Libre 2 which is provided on NHS prescription.
Leave a comment (all fields required). Please note, we are unable to respond to individual comments posted here.